Vigabatrin for the Treatment of Cocaine Dependency

ClinicalTrials.gov ID: NCT01281202

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01281202. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 7:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The objective of this 26-28 week study is to demonstrate that the rate of cocaine dependent subjects treated with CPP-109 vigabatrin in addition to counseling, who completely stop use of cocaine in the last 2 weeks of the study's Treatment Phase (Weeks 8 and 9) will be higher than seen in subjects treated with placebo in addition to counseling.

Study identification

NCT ID: NCT01281202
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2, Phase 3
Lead sponsor: Catalyst Pharmaceuticals, Inc.; Industry
Enrollment: 207 participants

Conditions and interventions

Conditions

Interventions

Vigabatrin Drug
Matching Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 2011 (Type not available)
Primary completion: Oct 2012 (Actual)
Completion: Dec 2012 (Actual)
Last update posted: May 18, 2016

2011 – 2012

United States locations

U.S. sites: 13
U.S. states: 11
U.S. cities: 13

Facility	City	State	ZIP	Site status
Matrix Institute on Addictions	Los Angeles	California	90016	—
Friends Research Institute	Torrance	California	90502	—
VA Medical Center	Denver	Colorado	80220	—
University of Miami School of Medicine	Miami	Florida	33136	—
NeuroPsychiatric Research & Practice Assoc., Ltd.	Oak Brook	Illinois	60523	—
Mountain Manor Treatment Center @ Baltimore	Baltimore	Maryland	21229	—
Boston University School of Medicine	Boston	Massachusetts	02118	—
Pacific Institute for Research and Evaluation	Albuquerque	New Mexico	87102	—
Western Psychiatric Inst. and Clinic	Pittsburgh	Pennsylvania	15213	—
Medical University of South Carolina	Charleston	South Carolina	29403	—
Pillar Clinical Research, LLC	Dallas	Texas	75243	—
University of Texas Health Science Center at Houston	Houston	Texas	77054	—
George E Wahlen VA Medical Center	Salt Lake City	Utah	84148	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01281202, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 18, 2016 · Synced Nov 12, 2026